Fascinating, innovative research. We haven't had any new treatments for glaucoma, other than lowering eye pressure with various drops, for many decades. The possible NAION associated with Ozempic and GLP1 drugs x.com/DoctorPodcasts/status/… may also benefit from this new treatment.

EPISODE 170: New FDA-Accelerated approval for BEQALZI pill to treat Mantle Cell Lymphoma cancers that are resistant to or recur with older treatments. Watch video podcast with @MichaelWangMD who explains the disease and BEQALZI made by @BeOneMedicines. TIMELINE / CHAPTERS: - Introduction & Welcome - Meet Dr. Michael Wang (MD Anderson Cancer Center) - What Is Lymphoma? (Liquid Cancers vs. Solid Tumors) - What Makes Mantle Cell Lymphoma Unique & Difficult to Treat? - Who Gets Mantle Cell Lymphoma? (Demographics & Risk Factors) - Symptoms of Mantle Cell Lymphoma - How MCL Is Diagnosed: Biopsies, Markers & Flow Cytometry - The Evolution of Treatment: Moving Beyond Chemotherapy - Targeted Therapies: BTK Inhibitors & CAR T-Cell Therapy - Understanding BCL-2 Inhibitors in Cancer Mitochondria - BEQALZI (Sonrotoclax): Breakthrough BCL-2 Inhibitor - What Is FDA Accelerated Approval? - BEQALZI Clinical Trial Results & Response Rates - Dosing & Treatment Duration (Once-Daily Pill) - Availability & Sonrotoclax vs. Venetoclax - BeOne Medicines & Global Collaboration - Conclusion & Closing Remarks

EPISODE 168: New FDA-Approved Gastro-Esophageal Cancer Breakthrough: How ZIIHERA Works; Oncologist Explains. What is ZIIHERA, and how is this newly FDA-approved targeted therapy transforming the treatment of advanced HER2-positive gastroesophageal cancer? In this episode of DoctorPodcasts: Cykiert Files, host Dr. Robert Cykiert is joined by two world-renowned oncology experts: • Dr. Geoffrey Ku – Associate Attending Physician, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) & Phase 3 trial investigator. • Dr. Robert Iannone – Executive Vice President, Global Head of R&D, and Chief Medical Officer at Jazz Pharmaceuticals @JazzPharma. Together, they break down the groundbreaking science behind ZIIHERA, the landmark HORIZON-GEA-01 Phase 3 trial results, managing treatment side effects (including diarrhea prophylaxis), biomarker testing (HER2 & PD-L1), and what this means for patients with metastatic and locally advanced esophageal, GE junction, and gastric adenocarcinoma cancers. 📌 In This Episode, You’ll Learn: • What gastroesophageal adenocarcinoma (GEJ cancer) is and key risk factors (acid reflux, Barrett’s esophagus, H. pylori). • How ZIIHERA’s unique bispecific HER2 antibody mechanism differs from standard therapies like Herceptin (trastuzumab). • Key survival and progression-free survival findings from the HORIZON-GEA-01 Phase 3 study. • Why ZIIHERA combined with immunotherapy benefits patients regardless of PD-L1 status. • Essential clinical guidance on managing and preventing GI side effects. • Why comprehensive biomarker and HER2 testing is vital for every patient. ⏱️ TIMELINE / CHAPTERS: 00:00 - Introduction to Gastroesophageal Cancer & ZIIHERA 00:43 - Introducing Dr. Geoffrey Ku (MSKCC) & Dr. Robert Iannone (Jazz Pharmaceuticals) 02:16 - What is Gastroesophageal Adenocarcinoma (GE Junction & Stomach Cancer)? 03:27 - Risk Factors: Acid Reflux, Barrett’s Esophagus, Obesity & H. Pylori 06:43 - Why Esophageal and Stomach Cancers Are Often Diagnosed Late 09:17 - Understanding HER2-Positive Cancer & Key Biomarkers (PD-L1, MMR, Claudin 18.2) 12:25 - Evolution of 1st-Line Treatment: Chemo, Trastuzumab & Immunotherapy 14:06 - How ZIIHERA (Zanidatamab) Was Developed & Mechanism of Action 17:03 - Biliary Tract Cancer Approval to Gastroesophageal Phase 3 Trials 19:30 - HORIZON-GEA-01 Phase 3 Trial Design & FDA Approval Indications 20:56 - Efficacy Across PD-L1 Positive and Negative Patients 22:20 - Metastatic vs. Locally Advanced Disease & Potential Curative Setting 26:13 - Safety Profile & Managing Side Effects (Diarrhea Prophylaxis Protocols) 31:08 - Cardiac Monitoring & Drug Tolerability 31:47 - Dosing, Administration Route & Treatment Duration 33:28 - Overall Survival & Progression-Free Survival Data Breakdown 39:16 - Patient Quality of Life During Treatment 40:17 - Encouragement for Patients & Families Considering Targeted Therapy 44:06 - Nationwide Availability & Global Regulatory Status (Project Orbis) 46:11 - The Critical Importance of Routine HER2 Biomarker Testing 48:11 - Future Applications of ZIIHERA & Jazz Pharmaceuticals Oncology Pipeline 51:09 - Concluding Remarks & Summary 🔔 Please subscribe to DoctorPodcasts: Cykiert Files for expert discussions on medical breakthroughs, clinical trials, and healthcare innovations. Disclaimer: This video podcast is for educational and informational purposes only and does not constitute personalized medical advice. Please consult your physician or qualified healthcare provider regarding specific medical conditions or treatments. #EsophagealCancer #ZIIHERA #StomachCancer #Oncology #CancerResearch #HER2Positive #Immunotherapy #CancerBreakthrough #MedicalPodcast #JazzPharmaceuticals #Cykiert #DoctorPodcasts

Episode 167: Sanofi FDA-Approved Breakthrough Cancer Treatment Technology Is Transforming Multiple Myeloma Care. In this episode we explore the groundbreaking advancements in cancer therapy and how Sanofi’s @sanofi new FDA-approved treatment Sarclisa Escena via a CirCLIQ On‑Body Injector pro.campus.sanofi/us/product… is revolutionizing multiple myeloma patient care and improving patients' quality of life. It's also benefiting physician and healthcare provider efficiencies while reducing healthcare costs. Learn how this targeted therapy works from Mayo Clinic @MayoClinic Multiple Myeloma expert, Sikander Ailawadhi, M.D., mayoclinic.org/biographies/a…, the clinical data behind its approval, and what this means for patients, oncologists, and the future of oncology treatments. ⏱️ TIMESTAMPS / CHAPTERS 00:00 - Introduction to Multiple Myeloma & Recent Breakthroughs 03:15 - What is Multiple Myeloma? (Disease Overview) 07:45 - The Science Behind Sanofi’s FDA-Approved Treatment 12:30 - Key Clinical Trial Results & Patient Outcomes 18:10 - How This Treatment Compares to Standard of Care 23:40 - Future Outlook for Multiple Myeloma Therapies 28:10 - Final Thoughts & Summary 👍 Like this video if you found it informative, and FOLLOW DoctorPodcasts: Cykiert Files for in-depth medical discussions, expert interviews, and healthcare breakthroughs. 🔔 DISCLAIMER The information provided in this video podcast is for educational and informational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. 🏷️ HASHTAGS #MultipleMyeloma #CancerResearch #Oncology #FDAApproval #CancerTreatment #MedicalBreakthrough #DoctorPodcasts #CirCLIQ #OnBodyInjector #Sanofi #Sarclisa #SarclisaEscena #Cykiert

EPISODE 166: Colon-rectal cancer is one of the leading causes of cancer-related deaths, yet it is highly treatable and preventable when detected early. Three world-renowned experts discuss the latest breakthroughs in non-invasive colon cancer screening, including at-home @Cologuard stool DNA tests and newly FDA-approved @Freenome blood tests. 00:00 - Introduction: The Power of Non-Invasive Screening 02:36 - Welcome & Meet the Expert Panel 06:31 - Colorectal Cancer Trends & The Rise in Under-50 Cases 08:30 - Early Warning Signs vs. Asymptomatic Colon Cancer 09:09 - Why Screening Guidelines Lowered the Age to 45 10:40 - Why Do People Delay or Avoid Colonoscopies? 12:45 - What Is Cologuard & Multi-Target Stool DNA Testing? 15:10 - Who Is Eligible for Non-Invasive Screening? 16:04 - Step-by-Step: The At-Home Cologuard Experience 17:36 - Do At-Home Tests Replace a Colonoscopy? 18:47 - Accuracy & Clinical Data 20:23 - Patient Adherence Rates & Common Misconceptions 22:58 - Riley Ennis & The Story Behind Freenome 24:05 - How SimpleScreen CRC Uses Multiomics & AI 25:34 - SimpleScreen CRC Accuracy & PREEMPT CRC Trial Data 27:02 - Where Blood Tests Fit in the Screening Cascade 28:24 - Overview of New FDA-Approved Non-Invasive Options 29:07 - Cologuard vs. Cologuard Plus: What Changed? 30:05 - Can Stool and Blood Tests Be Combined? 31:22 - Awareness Campaigns & Educating the Public 33:06 - The Future of Colonoscopies & Early Detection 34:43 - Beyond CRC: Multi-Cancer Early Detection (Lung & Pancreas) 36:26 - Insurance & Medicare Coverage Explained 38:52 - Final Takeaways & Advice for Patients

EPISODE 165: Ozempic and GLP-1 drugs are sagging faces as fast as they shrink waistlines. Top Miami plastic surgeon DrNathan.com explains why so many people look older after the weight comes off — and how they actually fix the facial skin sag without the pulled wind tunnel look. Would you get surgery after losing 50+ lbs on these drugs? Dr. Nathan also discusses breast implants, explants & exchanges; and why more men are having plastic surgery because of Zoom.

EPISODE 164: High TriGlycerides don’t just raise heart risk. Over 500 & they can trigger life-threatening pancreatitis. Harvard cardiologist @BrianBergmark on the FDA-expanded use of Tryngolza from @ionispharma. TG down ~50–70%. Acute pancreatitis down 85% in the trials. Most people only hear about LDL, bad cholesterol. This is the other important number on your lipid panel. #triglycerides #cardiology #Tryngolza

RUNNING Interlude 43: Resting pulse improving. Happy as long as it doesn't go to zero.

RACE Interlude 42: Ran 10k (6.2 mile) race with @CentralParkTC at hilly Central Park (1x Harlem Hill + 1x Cat Hill) at 7:30 AM this morning (Temp 69, DewPoint 62). Did it in 59:41 or 9:37/mile. List of 10K races in Central Park same course: 8/22/26> 9:37/mile 1/10/26> 9:10/mile 8/23/25> 9:50/mile 2/2/25> 10:55/mile 1/8/22> 10:02/mile 1/4/20> 10:16/mile 10/6/18> 9:00/mile

RACE Interlude 41: Ran 5k (3.1 mile) race with @CentralParkTC @ Icahn Stadium 400 meter outdoor track on 8/18/26 @ 8 PM (Temp 82, DewPoint 66). 8/18/26> 28:48 or 9:16/mile. Previous 5K results: 8/8/26 Outdoor Road hilly (Temp 74, DewPoint 72)> 27:59 or 9:01/mile 8/1/26> 8:52/mile 6/14/26> (outdoor 400M track): 8:45/mile 2/21/26 > (hilly outdoor road) 9:06/mile 12/30/25> (indoor 200m track) 8:47 min/mile 11/1/25 (flat outdoor road)> 8:34/mile 8/9/25 (same course as 8/8/26)> 9:03/mile 7/12/25 (outdoor 400 m track)> 8:59/mile 6/12/25 (outdoor 400 m track)> 9:47/mile 11/1/14 (outdoor road)> 8:06/mile

EPISODE 163: FIRST EVER: Kidney & liver tissues bioprinted in space just returned to Earth on a @SpaceX Dragon🚀. World’s leading expert, Anthony Atala, M.D. of @WFIRMnews explains how SpaceX’s frequent, reusable cargo flights have transformed the field. “It’s almost like booking an airline trip,” says Robert Cykiert, M.D. of @DoctorPodcasts. Full exclusive video interview 👇 @elonmusk @NASA @rookisaacman @NASAAdmin @Axiom_Space

EPISODE 162: New @American_Heart Statement says up to ~5 cups a day is generally safe for most adults and may be linked to lower risk of heart disease, stroke, heart failure & diabetes. We talked with the Statement lead author himself - cardiologist Gregory Marcus, M.D. @gregorymmarcus (UCSF) — about caffeine, coffee, energy drinks, heart attacks, strokes, diabetes, AFib and more. Watch the full breakdown.

RUN/RACE Interlude 40: Did a 12-Mile race in Central Park this morning with @CentralParkTC (2x Harlem Hill + 2x Cat Hill) (Temp 68, DewPoint 60). Did it in 2 hours & 7 minutes, or 10:37/mile. Previous 12-Mile races on same course: 8/16/25> 12:01/mile 8/24/24> 13:09/mile 8/20/22> 12:26/mile 7/21/18> 9:47/mile

Episode 161: 67%. That’s how much the new FDA-approved COVID pill XOCOVA @XOCOVA reduced symptomatic infection after exposure in its Phase 3 trial. this is the first oral post-exposure antiviral in the U.S. I interviewed the Shionogi @ShionogiUS physicians who developed it. Find out how it works, who it’s for, and the full data. Watch here:

RUN/RACE Interlude 39: Ran Harlem 5K (3.1 mile) outdoor road race on 8/8/26 with @CentralParkTC (Temp 74, DewPoint 72). Did it in 27:59 or 9:01/mile. That's 6 seconds faster than 1 year ago on same course! Previous 5K times: 8/1/26> 8:52/mile 6/14/26> (outdoor 400M track): 8:45/mile 2/21/26 > (hilly outdoor road) 9:06/mile 12/30/25> (indoor 200m track) 8:47 min/mile 11/1/25 (flat outdoor road)> 8:34/mile 8/9/25 (same course as 8/8/26)> 9:03/mile 7/12/25 (outdoor 400 m track)> 8:59/mile 6/12/25 (outdoor 400 m track)> 9:47/mile 11/1/14 (outdoor road)> 8:06/mile

EPISODE 160: Breakthrough cholesterol pill LIPFENDRA made by @Merck just FDA-approved: Game-changing, without the injections. LIPFENDRA is a brand-new oral cholesterol pill about to change everything for heart attack and stroke prevention. In this must-watch episode 160 of DoctorPodcasts, host Dr. Robert Cykiert discusses cholesterol dangers and treatments with two of the world’s leading cardiologists and lipid experts — Dr. Norman Lepor (Cedars-Sinai, UCLA) and Dr. Christy Ballantyne (Baylor College of Medicine). Watch this deep dive into LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor just approved by the FDA. They break down: • Why LDL cholesterol is the #1 driver of heart attacks and strokes (1.5 million U.S. deaths yearly) • Genetics vs lifestyle: why some people still have sky-high cholesterol on perfect diets • Exact LDL targets based on your risk (and why “normal” on lab reports is often too high) • How Lipfendra works differently from injectable cholesterol medications, Repatha, Praluent, Leqvio • Real efficacy (up to ~60% LDL reduction), safety data, side effects, cost, and who should take it • When the big cardiovascular outcomes trial results are coming. If you or a loved one has high cholesterol, familial hypercholesterolemia, statin intolerance, injection phobia or just wants the latest breakthrough in heart disease prevention, this conversation is essential. Like, subscribe, and share to help more people protect their hearts, brains and other organs! Full Timeline: 0:00 – Welcome to DoctorPodcasts Episode 160 0:33 – Why cholesterol is a top cause of heart attacks & strokes 0:51 – Introducing world experts Dr. Norman Lepor & Dr. Christy Ballantyne 2:38 – What exactly is cholesterol and why does the body need it? 3:58 – How high LDL damages arteries and builds deadly plaque 5:18 – LDL vs HDL vs triglycerides vs Lipoprotein(a) explained 7:00 – Why some people have high cholesterol even on a perfect diet (genetics) 9:17 – When should you start checking cholesterol & advanced tests (Lp(a), ApoB, hs-CRP)? 12:14 – Familial hypercholesterolemia: how common is it and what to do 15:20 – What are truly safe LDL cholesterol goals today? 17:24 – How effective are diet, exercise & lifestyle for genetic high cholesterol? 19:28 – Which other arteries does high cholesterol clog (brain, legs, etc.)? 20:28 – How statins (Lipitor, Crestor) work and why they’re still first-line 22:45 – Why many patients need more than just a statin 24:49 – PCSK9 inhibitors: the injectable game-changers so far 25:55 – Deep dive into Lipfendra: the new oral PCSK9 inhibitor pill 27:57 – Key advantages of the oral pill vs injections (convenience, adherence, storage) 29:41 – When doctors will prescribe Lipfendra (add-on or monotherapy) 31:23 – Perfect for patients who can’t tolerate statins or hate injections 32:28 – Side effects and overall safety profile from the trials 34:04 – Who should not take Lipfendra (contraindications) 34:39 – Cost and insurance coverage expectations 35:33 – How fast does Lipfendra lower LDL and how long does the effect last? 36:48 – Is it as effective as injectable PCSK9 inhibitors like Repatha? 38:03 – Will Lipfendra be a true game-changer? 39:13 – Cardiovascular outcomes data: do these drugs actually prevent heart attacks & death? 42:04 – Working with Merck on the trials and when outcomes results arrive 44:56 – Will AI speed up future cholesterol drug discovery? 46:33 – Final thoughts and thank you #Lipfendra #Cholesterol #PCSK9 #HeartHealth #LDL #Cardiology #HeartAttackPrevention #StrokePrevention #NewCholesterolDrug #FDAApproved #DoctorPodcasts #Cykiert #Stroke #Dementia Please LIKE, Subscribe, Share for more expert interviews on the latest medical breakthroughs that can save lives!

RUN/RACE Interlude 38: Ran 2 races at ICahn Stadium outdoor 400M track on Wednesday 8/5/26 with @CentralParkTC. (Temp 76, DewPoint 75). (DewPoint 75 feels like running in soup). 1) 1600 Meters (0.994 miles) in 8:13 or (8:16/mile) 2) 800 Meters (0.497 miles) in 3:57 Previous 1-mile races: 6/14/26> (outdoor 400m track) 8:13/mile 5/2/26> (400m Icahn outdoor track) 8:08/mile (Temp 83, DewPoint 57) 4/4/26> (200m indoor track)> 8:02 3/20/26> (200m indoor track)> 7:58 2/12/26> (200m indoor track)> 8:05 9/7/25> (5th Ave. Mile outdoor)> 7:43 5/23/25> (200m indoor track)> 8:39 5/2/25> (400m outdoor track)> 8:33 3/8/25> (200m indoor track)> 8:41 Previous 800-meter races: 6/14/26 (outdoor 400m track)> 3:52 (Temp 83, DewPoint 57)

RUN/RACE Interlude 37: Ran the very hilly Park Avenue 5K (3.1 miles) race with @CentralParkTC on Saturday 8/1/26. (Temp 74, DewPoint 66). Did it in 27:32 or 8:52/mile. Previous 5K races: 6/14/26> (outdoor 400M track): 8:45/mile 2/21/26 > (hilly outdoor road) 28:15 or 9:06/mile 12/30/25 (indoor 200m track)> 8:47 min/mile 11/1/25 (flat outdoor road)> 8:34/mile 8/9/25 (outdoor road)> 9:03/mile 7/12/25 (outdoor 400 m track)> 8:59/mile 6/12/25 (outdoor 400 m track)> 9:47/mile 11/1/14 (outdoor road)> 8:06/mile

EPISODE 159: The Dangerous Sleep Disorders Many Doctors Miss: Narcolepsy Type 1 & 2 + Idiopathic Hypersomnia. Today we dive into two rare but life-disrupting sleep disorders: narcolepsy and idiopathic hypersomnia. People with these conditions don’t just feel tired — they can fall asleep suddenly while driving, talking, or working, or sleep 11+ hours and still feel completely unrefreshed with intense brain fog and sleep drunkenness. Our guest is world-renowned sleep expert Dr. Logan Schneider, board-certified neurologist and sleep medicine specialist, Adjunct Clinical Associate Professor at Stanford University, and Clinical Lead for Sleep Health at Google. We cover causes (including the loss of the brain chemical orexin/hypocretin), symptoms like cataplexy, diagnosis, the only FDA-approved medication for idiopathic hypersomnia (Xywav), made by Jazz Pharmaceuticals @JazzPharma, lifestyle strategies, common myths, and how to find the right specialist. Timestamps: 0:00 – Introduction & episode overview 1:07 – Meet Dr. Logan Schneider 2:06 – What are sleep disorders and why they matter 3:12 – How common is excessive daytime sleepiness? 5:28 – What is narcolepsy and its main symptoms 6:55 – Sleep attacks and the danger of falling asleep while driving 8:04 – Type 1 narcolepsy: the orexin/hypocretin deficiency 10:25 – Is it autoimmune? What triggers it? 10:29 – How is narcolepsy diagnosed? 12:10 – Narcolepsy Type 2 explained 13:42 – What is cataplexy and REM sleep? 15:07 – Who gets narcolepsy (age & gender) 16:55 – Idiopathic hypersomnia: how it differs from narcolepsy 18:24 – Sleeping 9–11 hours and still exhausted 19:24 – Brain fog and “sleep drunkenness” 21:06 – Does coffee help these disorders? 22:39 – Xywav (low-sodium oxybate): how it works for both conditions 26:32 – Why the low-sodium version matters for heart health 28:56 – REMS program and why it’s a controlled substance 31:45 – Who is a candidate for Xywav? 35:33 – Lifestyle tips and support strategies 37:02 – Common misconceptions about these disorders 40:08 – Do you need a sleep study before treatment? 42:10 – Who can prescribe Xywav? 44:14 – How to find a sleep specialist near you 45:50 – Final message: “Sleepiness is red alert” Subscribe for more expert medical interviews! #Narcolepsy #IdiopathicHypersomnia #SleepDisorders #ExcessiveDaytimeSleepiness #Cataplexy #Xywav #SleepMedicine #BrainFog #Hypersomnia #NarcolepsyAwareness #SleepHealth #DoctorPodcasts #Cykiert #sleep